I'm planning to invest in Novo Nordisk (NVO) as I move my funds to the US. Holding this stock seems beneficial, and I don't see any significant differ...
Read
More
I'm planning to invest in Novo Nordisk (NVO) as I move my funds to the US. Holding this stock seems beneficial, and I don't see any significant differences in markets. It's a solid long-term play, and I'm excited about its potential growth.
Despite the recent drop, I see potential in NVO as the pharmaceutical sector reacts to broader market conditions. With mixed expectations about new le...
Read
More
Despite the recent drop, I see potential in NVO as the pharmaceutical sector reacts to broader market conditions. With mixed expectations about new leadership in health, I believe NVO may rebound as it remains a strong contender in the industry.
I just bought shares of Novo Nordisk because JPMorgan placed it on their ‘Positive Catalyst List’ with an overweight rating. Their bullish expectation...
Read
More
I just bought shares of Novo Nordisk because JPMorgan placed it on their ‘Positive Catalyst List’ with an overweight rating. Their bullish expectation around the upcoming study data for CagriSema suggests we could see at least a 10% increase in stock price, which makes it a solid swing trade.
I'm considering buying put options on NVO as the upcoming phase III study results in December might reveal if they can maintain their competitive edge...
Read
More
I'm considering buying put options on NVO as the upcoming phase III study results in December might reveal if they can maintain their competitive edge. If they fail to secure a strong replacement for their GLP-1 drug, the stock could take a hit, making this an interesting play.
With all the outrage around the pricing of OZEMPIC and the scrutiny from lawmakers, it seems like Novo Nordisk could face pressure that might negative...
Read
More
With all the outrage around the pricing of OZEMPIC and the scrutiny from lawmakers, it seems like Novo Nordisk could face pressure that might negatively impact their stock. With the increasing focus on drug prices, I believe taking a short position makes sense in the current environment.